Citius rises on patient enrollment for study of hemorrhoids treatment

Citius Pharmaceuticals

03/04/2023 16:48

** Shares of drug developer Citius Pharmaceuticals Inc
 CTXR.O  rise 5.1% to $1.23
    ** Co completes patient enrollment in mid-stage study of its
Halo-Lido (CITI-002), a topical formulation for the relief of
hemorrhoids
    ** Topline results anticipated by the end of Q2 2023
    ** Hemorrhoids are a gastrointestinal disorder characterized
by pain, swelling, itching, tenderness and bleeding
    ** Brokerage H.C. Wainwright & Co believes Halo-Lido has
potential to become first FDA-approved prescription product, and
look for the mid-stage trial results to be a positive catalyst
    ** Including sessions gains, stock up ~53% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))